CCCC C4 Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1662579 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.2%
TTM net income YoY23.5%
TTM EPS YoY62.3%
Revenue 3-yr CAGR16.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-315.9%
Net margin-282.2%
FCF margin-247.1%
EBITDA margin-311.2%
Returns
ROE-47.6%
ROA-30.5%
ROIC (approx.)-55.3%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets31.2%
Debt / equity0.00x
Current ratio5.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-3.8%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $35.95M | $35.58M |
| R&D expense | $104.24M | $110.64M |
| SG&A expense | $36.20M | $42.12M |
| Operating income | -$115.22M | -$119.61M |
| Pretax income | -$104.87M | -$105.19M |
| Income tax | $121,000 | $131,000 |
| Net income | -$104.99M | -$105.32M |
| EBITDA | -$113.26M | -$117.80M |
| EPS (basic) | -1.27 | -1.52 |
| EPS (diluted) | -1.27 | -1.52 |
| Weighted avg. shares (diluted) | 82.89M | 69.37M |
| Balance sheet | ||
| Cash & equivalents | $74.60M | $58.94M |
| Receivables | $2.40M | $3.10M |
| Current assets | $258.11M | $257.77M |
| PP&E, net | $4.74M | $5.84M |
| Total assets | $359.07M | $349.60M |
| Current liabilities | $33.03M | $45.18M |
| Total liabilities | $102.49M | $133.62M |
| Shareholders' equity | $256.59M | $215.99M |
| Shares outstanding | 96.91M | 70.63M |
| Cash flow statement | ||
| Operating cash flow | -$98.69M | -$65.16M |
| Capital expenditure | $607,000 | $180,000 |
| Free cash flow | -$99.30M | -$65.34M |
| Investing cash flow | -$8.60M | -$51.27M |
| Financing cash flow | $126.40M | $45.34M |
| Depreciation & amortization | $1.96M | $1.82M |
| Stock-based compensation | $19.10M | $29.66M |
| Share buybacks | $193,000 | $194,000 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.